Real-World Evidence of the use of Tisagenlecleucel for Patients with Relapsed/Refractory Agressive B-Cell Lymphomas. The Spanish Experience
Por:
Iacoboni, G, Catala, E, Pina, JMS, Bailen, R, Mussetti, A, Sancho, JM, Ribera, JM, Sureda, A, Kwon, M, Coronel, MLP, Bosch, F and Barba, P
Publicada:
1 dic 2020
Resumen:
Filiaciones:
Iacoboni, G:
Vall dHebron Univ Hosp, Barcelona, Spain
Catala, E:
Vall dHebron Univ Hosp, Barcelona, Spain
Pina, JMS:
12 Octubre Univ Hosp, Madrid, Spain
Bailen, R:
Gregorio Maranon Univ Hosp, Madrid, Spain
Mussetti, A:
ICO IDI BELL, Lhospitalet De Llobregat, Spain
:
ICO IJC Hosp Germans Trias & Pujol, Badalona, Spain
:
ICO IJC Hosp Germans Trias & Pujol, Badalona, Spain
Sureda, A:
ICO IDI BELL, Lhospitalet De Llobregat, Spain
Kwon, M:
Gregorio Maranon Univ Hosp, Madrid, Spain
Coronel, MLP:
12 Octubre Univ Hosp, Madrid, Spain
Bosch, F:
Vall dHebron Univ Hosp, Barcelona, Spain
Barba, P:
Vall dHebron Univ Hosp, Barcelona, Spain
|